|Industry||Pharmaceuticals, Natural products|
|Headquarters||Irvine, California, United States|
|Key people||Frank Jaksch
ChromaDex is a publicly traded natural products company based in Irvine, California. The company is most well known for its industry standard phytochemical testing laboratories and catalogue. In cooperation with the University of Mississippi, the company is currently exploring the effects of pterostiibene on humans.
ChromaDex has licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound trademarked as pTeroPure via the company's BluScience product line.
In 2010, ChromaDex won the North American Frost & Sullivan Award for Most Promising Ingredient of the Year for pTeroPure pterostilbene.
ChromaDex was founded in 1999. According to a Standard & Poor's research report, the company was created "in response to growing demand for natural product reference standards, materials and services. It has worked to establish itself as an industry leader in nutraceutical and botanical certification, and even publishes its own manual outlining specifications for phytochemicals." On July 14, 2008 ChromaDex merged with CDI Acquisition, a subsidiary of Cody Resources Inc. On July 29, 2008 the company completed a private placement agreement, which yielded gross proceeds of $4.67 million.
Later in 2008, ChromaDex (OTCQB: CDXC) became a publicly traded company. Shares of ChromaDex are traded on the OTC Markets Venture Marketplace. As of April 2012, there were 90.1 million shares outstanding.
The ChromaDex catalogue "provides phytochemical reference standards, botanical reference materials and research grade materials for the natural products industry." The company sells over 3,000 phytochemicals and 470 botanical reference materials in its catalogue. The company's products reach a wide range of markets including food & beverage, pharmaceutical, cosmeceutical, research organizations and governmental groups.
BluScience and pTeroPure
ChromaDex received exclusive worldwide patent rights for its pTeroPure pterostilbene product based on the technology licensed from the University of Mississippi and the USDA. Pterostilbene belongs to a class of compounds called phytoalexins, which are antimicrobial substances synthesized de novo by plants that accumulate rapidly at areas of incompatible pathogen infection.
Pterostilbene and resveratrol have similar pharmacologic properties. However pterostilbene has exhibited advantages over resveratrol including superior biological activity, better oral bioavailability, and a slower metabolizing time, which provides more time for the compound's antioxidant activities to act.
According to the USDA, "pterostilbene is one of many aromatic hydrocarbons called stilbenes." ChromaDex's pTeroPure is an identical form of trans-pterostilbene. The company sells pTeroPure under its BluScience product line.
Nicotinamide riboside technology
On July 13, 2011, Cornell University announced it granted ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR). NR, a vitamin found in milk, is a more potent version of niacin (vitamin B3). Like niacin, NR is a precursor to nicotinamide adenine dinucleotide (NAD), which is elevated by a calorie restricted diet. Increasing cellular NAD has demonstrated cell-protective and positive metabolic effects. In laboratory tests, "NR has shown promise for improving cardiovascular health, glucose levels and cognitive function and has demonstrated evidence of anti-ageing effects."
Contract research services & capabilities
ChromaDex also offers contract research services that help customers source raw materials, identify new compounds and develop processes for large scale manufacturing. The company also has a number of analytical capabilities including gas chromatography, mass spectrometry, and high performance liquid chromatography.
- Standard & Poor's (2013-10-05). "ChromaDex: Standard & Poor's Factual Report". Standard & Poors. p. 10. Retrieved 2013-10-10.
- Neeb, Matthew (2011-06-20). "Ole Miss grants exclusive patent rights to ChromaDex Corp.". The Daily Mississippian. Retrieved 2012-05-25.
- "Frost & Sullivan Recognizes ChromaDex for the Unique Potential Its Commercially Available Product Offers in the Human Nutrition Industry". Yahoo Finance. 5-3-2011. Retrieved 2012-05-25.
- Gould, David (5-3-2011). "Billionaire Phillip Frost: A Case Study In Synergy". TREFIS. Retrieved 2012-05-29.
- "ChromaDex Corp. Names Consumer Products Veteran Jeffrey Himmel CEO". 2012-1-23. Retrieved 2012-05-29.
- "Functional Ingredients". 5-10-2009. Retrieved 2012-05-29.
- "ChromaDex Red Chip Small Cap Investor Conference Presentation". 2011-04-26. Retrieved 2012-05-29.
- IM Kapetanovic et al (November 2010). "Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats". Cancer Chemother Pharmacol 68 (3): 593–601. doi:10.1007/s00280-010-1525-4. PMC 3090701. PMID 21116625.
- CM Remsberg et al (February 2008). "Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity". Phytother Res 22 (2): 169–79. doi:10.1002/ptr.2277. PMID 17726731.
- P Ferrer et al (January 2005). "Association between Pterostilbene and Quercetin Inhibits Metastatic Activity of B16 Melanoma". Neoplasia 7 (1): 37–47. doi:10.1593/neo.04337. PMC 1490314. PMID 15736313.
- Pons, Luis. "Pterostilbene’s Healthy Potential". USDA. Retrieved 2012-05-29.
- "Best of 2011 Ingredient Supplier: ChromaDex". Nutritional Outlook. Retrieved 2012-05-29.
- Belenky P; Bogan KL; Brenner C (2007). "NAD+ metabolism in health and disease" (PDF). Trends Biochem. Sci. 32 (1): 12–9. doi:10.1016/j.tibs.2006.11.006. PMID 17161604. Retrieved 2007-12-23.